CD38-Targeted<sup>89</sup>Zr-DFO-Daratumumab PET of Myeloma: Immuno-PET Impacting Clinical Care
Gary A. Ulaner, Jason S. Lewis, Ola Landgren
Abstract
Currently, the determination of disease burden in multiple myeloma is suboptimal. Myeloma cells may not secrete abnormal immunoglobulins or free light chains, limiting blood and urinary analysis ([1][1]). Imaging by radiography and MRI is limited, and approximately 30% of myeloma lesions are not
Topics & Concepts
DaratumumabMedicineMultiple myelomaNuclear medicineInternal medicineLenalidomideMultiple Myeloma Research and TreatmentsPeptidase Inhibition and AnalysisHER2/EGFR in Cancer Research